BrainMeta'   Connectomics'  

Welcome Guest ( Log In | Register )

 
Reply to this topicStart new topic
> VALDOXAN (Agomelatine), Novel MELATONERGIC antidepressant
Kazan
post Jul 09, 2009, 05:47 PM
Post #1


Newbie
*

Group: Basic Member
Posts: 11
Joined: Jul 06, 2009
Member No.: 32229



As information for all I add that Servier Laboratories (of Stablon) is starting to market a new antidepressant named Valdoxan (Agomelatine).

As I understand it just coming out in Britain. This is a very novel antidepressant. It is a Melatonergic in action, it increases (agonist) the activity of the receptors for Melatonin at M1 and M2 and decreases (antagonist) the activity of the receptor for Serotonin 5HT2c.

Novartis obtained the license to market it in the U.S. and has submitted it to the FDA where, I believe, it lingers until their patent on their own antidepressant (SSRI) expires.

Since it is from Servier, the innovator with Survector and Stablon there is hope that it may also be effective, but that remain to be seen—if it is effective it may “run of the mill” and NOT have neuroenhancing or activating properties.

I've been researching this antidepressant online for years and feel convinced that it must be totally different in its effect, but an actual trial is the only final determiner. The purported lack of side-effects or tolerability is paramount in its use.

I haven’t being able to locate a source at all yet, so would appreciate knowing if someone has
User is offlineProfile CardPM
Go to the top of the page
+Quote Post

Reply to this topicStart new topic
1 User(s) are reading this topic (1 Guests and 0 Anonymous Users)
0 Members:

 



Lo-Fi Version Time is now: 19th November 2017 - 04:33 PM


Home     |     About     |    Research     |    Forum     |    Feedback  


Copyright © BrainMeta. All rights reserved.
Terms of Use  |  Last Modified Tue Jan 17 2006 12:39 am

Consciousness Expansion · Brain Mapping · Neural Circuits · Connectomics  ·  Neuroscience Forum  ·  Brain Maps Blog
 · Connectomics · Connectomics  ·  shawn mikula  ·  shawn mikula  ·  articles